A needle under the skin beats a drip, for some nerve patients
Cochrane review of 360 CIDP patients finds under-skin immunoglobulin lowers relapse risk versus placebo, with milder side effects.
By The Weekend · · 5 min read
For people with chronic inflammatory demyelinating polyradiculoneuropathy, a maintenance injection under the skin now has solid evidence behind it: compared with a dummy treatment, subcutaneous immunoglobulin probably reduces how many patients get worse. The data come from four trials totaling 360 people, and the result holds up well enough that Cochrane's reviewers call it "probable" rather than merely "possible" — their highest confidence short of certainty.
Three trials, 360 people, and a verdict that took decades to arrive
CIDP is rare — most neurologists see only a handful of cases in a career — which is why it has taken this long to get a clean answer. The condition causes the immune system to attack the coating around nerves, producing slowly worsening weakness and numbness in the arms and legs. Left untreated, it can leave people unable to walk or grip a cup.
The standard long-term treatment has been intravenous immunoglobulin: purified antibodies, pooled from donated blood, dripped into a vein every few weeks. It works, but it requires a hospital or infusion clinic, a line in the arm, and hours in a chair. Subcutaneous immunoglobulin is the same basic drug — donated antibodies — delivered instead by injection into the fatty tissue under the skin, often by patients themselves at home.
The Cochrane review pooled three placebo-controlled trials of SCIg given as maintenance therapy, plus one small trial comparing SCIg against IVIg as a short-term induction treatment. The maintenance trials ran from 10 to 26 weeks and involved 360 people combined — most of them men, average age 55, drawn from sites worldwide. The smallest trial had 20 participants; the largest, 172. That's not a huge dataset for a chronic disease, but for a condition this uncommon, it represents years of recruitment effort across multiple continents.
The one number: fewer relapses, less grip loss, worse injection sites
The figure the whole result turns on is this: among people on SCIg maintenance treatment, fewer experienced a worsening in disability than among those on placebo. Grip strength also declined less, and disability scores worsened less, in the SCIg group. These aren't marginal trends — the reviewers rated the evidence "probable" on all three outcomes, meaning further research is unlikely to overturn the core finding, even if it might refine the exact size of the benefit.
The trade-off is local, not systemic. People injecting SCIg had a higher risk of side effects at the injection site — redness, swelling, soreness where the needle went in — but no higher risk of side effects affecting the rest of the body. That's a meaningful distinction for a drug delivered under the skin repeatedly, sometimes weekly, for years: the cost shows up as a sore patch of skin, not a systemic reaction.
Why "probably works" is a bigger claim than it sounds
It would be easy to read "probably reduces worsening" as hedging. It isn't. Cochrane's grading system treats "probable" as the second-highest tier of confidence a review can award, reserved for evidence unlikely to be reversed by future studies, even if the precise magnitude could shift slightly. Reaching that tier for a disease this rare, with trials this small, is itself notable — it means the signal was consistent across independent trials run by different sponsors in different countries, not a fluke from one well-designed study.
There's a funding wrinkle worth naming plainly: all four trials were partly or entirely funded by pharmaceutical companies that make immunoglobulin products. That doesn't invalidate the result — the effect sizes were consistent across trials from different manufacturers, which is harder to manufacture than a single favorable study — but it does mean no independent, publicly funded trial has yet replicated the finding from outside the industry that profits from it.
What the evidence still can't tell a patient choosing between a drip and a syringe
The honest gap is induction treatment — the initial push to improve disability in someone newly diagnosed or in a flare, as opposed to maintaining a patient who's already stable. Here the review found almost nothing: one small trial compared SCIg against IVIg for induction and found, from very limited data, no detectable difference in disability scores after five weeks. No trial has ever tested SCIg against placebo for induction. So the case for SCIg is a maintenance case only; nobody has shown it works as a first-line treatment for someone just starting therapy.
The other open question is how SCIg stacks up against IVIg specifically for long-term maintenance — not against a placebo, but against the treatment it would realistically replace. The review notes this comparison is largely missing. Patients and clinicians weighing convenience (home injection) against another real option (infusion center visits) don't yet have head-to-head maintenance data telling them whether one keeps disability more stable than the other. They only know both beat doing nothing.
What changes next for someone living with CIDP
For a patient currently on IVIg and tired of infusion appointments, this review offers something concrete: evidence strong enough to support switching to home-based subcutaneous injections for maintenance, with the main downside being manageable skin irritation rather than a different category of risk. For a patient newly diagnosed and needing induction treatment, the evidence gap means IVIg remains the better-studied first move, with SCIg's role confined, for now, to the maintenance phase that follows.
What happens next is more trials, and specifically the trial nobody has run yet: SCIg against IVIg, head to head, over months rather than weeks, measuring whether home injections keep a chronic nerve disease as stable as hospital infusions do. Until that exists, the honest answer for someone choosing between a drip and a syringe is that both keep the disease from getting worse — just not yet compared directly against each other, and not yet funded by anyone other than the companies selling both.